We narrowed to 11,868 results for: KIN

#198511-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-DIO-PdCO-mScarlet-WPRE (#198511). In addition to the viral particles, you will also receive purified pAAV_hSyn-DIO-PdCO-mScarlet-WPRE plasmid DNA. Syn-driven Cre-dependent expression of optimized PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

Sept. 27, 2024

Academic Institutions and Nonprofits only

#101064-AAV1

Ready-to-use AAV1 particles produced from pAAV_hsyn_NES-his-CaMPARI2-L398T-WPRE-SV40 (#101064). In addition to the viral particles, you will also receive purified pAAV_hsyn_NES-his-CaMPARI2-L398T-WPRE-SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator his-tagged CaMPARI2-L398T. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Moeyaert et al Nat Commun. 2018 Oct 25;9(1):4440. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#220588

Increase editing efficiency of retron and oligo recombineering

Seth Shipman

Lopez et al Nat Chem Biol. 2022 Feb;18(2):199-206. d

May 16, 2024

Academic Institutions and Nonprofits only

#198513-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#198516-AAV5

Ready-to-use AAV5 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#84471-AAV8

Ready-to-use AAV8 particles produced from pAAV-RAM-d2TTA::TRE-ChR2-WPREpA (#84471). In addition to the viral particles, you will also receive purified pAAV-RAM-d2TTA::TRE-ChR2-WPREpA plasmid DNA. RAM-containing and TRE-driven, ChR2 H134R mutant fused to EYFP. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sorensen et al Elife. 2016 Sep 23;5. pii: e13918. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#196219-AAV2

Ready-to-use AAV2 particles produced from pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR (#196219). In addition to the viral particles, you will also receive purified pAAV.CAG.FLEX.iGluSnFR3.v857.PDGFR plasmid DNA. CAG-driven, Cre-dependent third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

Aug. 6, 2025

Academic Institutions and Nonprofits only

#125712-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

Jan. 8, 2025

Academic Institutions and Nonprofits only